Delving into revolutionary SARS-CoV-2 vaccine approaches: Molecular and virological examinations; principles of SARS-CoV-2 vaccine platform

Fahime Edalat , Fatemeh Hosseini Tabatabaie , Afagh Moattari , Arash Letafati , Jamal Sarvari , Seyed Younes Hosseini
{"title":"Delving into revolutionary SARS-CoV-2 vaccine approaches: Molecular and virological examinations; principles of SARS-CoV-2 vaccine platform","authors":"Fahime Edalat ,&nbsp;Fatemeh Hosseini Tabatabaie ,&nbsp;Afagh Moattari ,&nbsp;Arash Letafati ,&nbsp;Jamal Sarvari ,&nbsp;Seyed Younes Hosseini","doi":"10.1016/j.vacune.2024.02.013","DOIUrl":null,"url":null,"abstract":"<div><p>Coronavirus disease (COVID-19) is an infectious illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It emerged in 2019 and quickly became a global pandemic, resulting in numerous deaths worldwide. Despite the devastating impact of SARS-CoV-2 on human life, it also spurred the development of advanced vaccine platforms. Within a remarkably short time frame, 11 vaccines have been approved for human use, marking a significant historical achievement. These include mRNA, whole inactivated, recombinant protein, and adenoviral vector platforms. Notably, these new-generation vaccine platforms represent a departure from previously utilized methods and form the backbone of SARS-CoV-2 preventive strategies. In order to enhance the efficacy of vaccines, it is crucial to have a comprehensive understanding of their underlying virological and immunological characteristics. The recent emergence of variant strains, particularly the Omicron variant, has raised doubts regarding the effectiveness of current vaccines and emphasized the need for a universal platform for future vaccinations.</p><p>This review focuses on discussing various vaccine platforms based on their molecular design, their ability to stimulate the immune system, safety concerns, potential efficacy against viral variants, and prospects for the future.</p></div>","PeriodicalId":101272,"journal":{"name":"Vacunas (English Edition)","volume":"25 1","pages":"Pages 109-127"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vacunas (English Edition)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2445146024000165","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Coronavirus disease (COVID-19) is an infectious illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It emerged in 2019 and quickly became a global pandemic, resulting in numerous deaths worldwide. Despite the devastating impact of SARS-CoV-2 on human life, it also spurred the development of advanced vaccine platforms. Within a remarkably short time frame, 11 vaccines have been approved for human use, marking a significant historical achievement. These include mRNA, whole inactivated, recombinant protein, and adenoviral vector platforms. Notably, these new-generation vaccine platforms represent a departure from previously utilized methods and form the backbone of SARS-CoV-2 preventive strategies. In order to enhance the efficacy of vaccines, it is crucial to have a comprehensive understanding of their underlying virological and immunological characteristics. The recent emergence of variant strains, particularly the Omicron variant, has raised doubts regarding the effectiveness of current vaccines and emphasized the need for a universal platform for future vaccinations.

This review focuses on discussing various vaccine platforms based on their molecular design, their ability to stimulate the immune system, safety concerns, potential efficacy against viral variants, and prospects for the future.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
深入研究革命性的 SARS-CoV-2 疫苗方法:分子和病毒学检查;SARS-CoV-2 疫苗平台的原理
冠状病毒病(COVID-19)是由严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)引起的一种传染病。它于 2019 年出现,并迅速成为一种全球性流行病,导致全球无数人死亡。尽管 SARS-CoV-2 对人类生命造成了毁灭性影响,但它也促进了先进疫苗平台的开发。在极短的时间内,已有 11 种疫苗获准用于人类,这是一项重大的历史性成就。这些疫苗包括 mRNA、全灭活、重组蛋白和腺病毒载体平台。值得注意的是,这些新一代疫苗平台与以前使用的方法不同,是 SARS-CoV-2 预防战略的支柱。为了提高疫苗的效力,全面了解疫苗的基本病毒学和免疫学特性至关重要。最近出现的变异株,尤其是 Omicron 变异株,使人们对目前疫苗的有效性产生了怀疑,并强调了为未来疫苗接种建立通用平台的必要性。本综述将重点讨论各种疫苗平台,包括其分子设计、刺激免疫系统的能力、安全性问题、对病毒变异株的潜在功效以及未来前景。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Review of vaccine packaging formats and their key features Could molecular farming be a game changing paradigm in the production of immune checkpoint inhibitors for cancer immunotherapy? Psychological characteristics and their impact on the efficacy and safety of COVID-19 vaccines Comments on “Prevalence of HCV among patients with HIV in Iran: A systematic review and meta-analysis” Measles eradication: Still a long and winding road
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1